Otros idiomas Johnson & Johnson Santiago S.E.

Acciones

JNJCL

US4781601046

Precio de cierre Santiago S.E. Otros sitios de cotización 00:00:00 14/06/2024			Varia. Cinco días.	Varia. 1 de enero.
155.930 ^CLP	0,00 %		0,00 %	+14,33 %

15/06	Johnson & Johnson anuncia que los resultados de última hora muestran que nipocalimab mejora significativamente la actividad de la enfermedad de Sjogren en un estudio de fase 2	CI
14/06	El regulador de la UE obliga a actualizar las etiquetas de las terapias CAR-T contra el cáncer	RE

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study	15/06
Johnson & Johnson Announces Late-Breaking Results Show nipocalimab Significantly Improves Sjögren's Disease Activity in A Phase 2 Study	15/06
Johnson & Johnson : Findings from landmark RESONATE 2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first line chronic lymphocytic leukaemia treatment with up to 10 years follow up	14/06
EU regulator mandates label updates on CAR-T cancer therapies	14/06
J&J : essai encourageant dans le myélome multiple récidivant	14/06
Johnson & Johnson : Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed duration IMBRUVICA® (ibrutinib) plus venetoclax as first line treatment for patients with chronic lymphocytic leukaemia, including those with high risk disease	14/06
J&J : les promesses de l'ibrutinib dans la LLC	14/06
J&J : résultats prometteurs pour Imbruvica dans la leucémie	14/06
Johnson & Johnson Reports Positive Long-Term Results for Talvey in Multiple Myeloma Study	14/06
Johnson & Johnson Announces TALVEY® (Talquetamab-Tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma	14/06
High-risk health workers can get routine Ebola vaccine, Gavi says	13/06
Xencor to Regain Exclusive Global Rights to CD20 x CD3 Bispecific T-Cell Engager	13/06
Xencor : J&J's Janssen Termintates Rights to Plamotamab	13/06
That's Stentertainment	13/06
High-risk health workers can get routine Ebola vaccine, says Gavi	13/06
Johnson & Johnson : to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Press Release	12/06
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy	12/06
Cancer victims ask court to block J&J talc bankruptcy	12/06
Johnson & Johnson agrees to pay $700M to settle talcum lawsuit with dozens of states	12/06
Sector Update: Health Care Stocks Softer Late Afternoon	11/06

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

Joseph Wolk, Director Financiero de J&J: Fin de la patente de su medicamento estrella

23 de enero 2024 a las 18:30